Core Viewpoint - The healthcare sector is highlighted as a critical area in the stock market, driven by the need for innovative therapies and medical technologies to address an aging population and rising chronic diseases. There are ten under-the-radar healthcare stocks identified as potential investment opportunities. Group 1: Company Highlights - **Certara**: Positioned to benefit from AI-driven transformations in medicine, providing bio-simulation software that accelerates drug development, with over 90% of novel drugs approved by the FDA since 2014 utilizing its technology [3][4]. - **Beam Therapeutics**: A clinical-stage biotech focusing on precision gene editing therapies for genetic diseases, with its lead candidate in phase 1/2 trials for sickle cell disease, showing promise for long-term growth [5][6]. - **Inspire Medical Systems**: Develops implantable devices for obstructive sleep apnea, reporting a 23% year-over-year revenue increase to $201 million, indicating strong market demand [8]. - **Insulet**: Specializes in tubeless insulin pump technology, targeting a revenue growth of 19% to 22% by 2025, with significant expansion opportunities in international markets [9]. - **Krystal Biotech**: Focuses on rare skin diseases, with its gene therapy expected to generate approximately $400 million in revenue this year, reinforcing its market position [10]. - **LifeMD**: Operates a telehealth platform with a 49% year-over-year revenue increase, driven by a partnership with Novo Nordisk, indicating potential for further growth [11]. - **Option Care Health**: Leading provider of home infusion services, positioned to benefit from the shift towards personalized healthcare [12]. - **Tempus AI**: Utilizes AI for precision medicine, projecting over 80% revenue growth this year to about $1.3 billion, highlighting its expansive data ecosystem [13]. - **TransMedics Group**: Innovates in organ transplantation with its FDA-approved Organ Care System, projecting a 30% revenue growth this year [14][15]. - **Veeva Systems**: Offers cloud-based software for life sciences, serving over 1,000 customers and positioned to capitalize on the industry's digital transformation [16].

Core Insights - Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of 38 cents for Q3 fiscal 2025, a decline of 39.7% year-over-year, but exceeded the Zacks Consensus Estimate by 11.76% [1] - Total sales for Q3 reached $38.99 billion, reflecting a year-over-year increase of 7.2% and surpassing the Zacks Consensus Estimate by 6.5% [2][9] - The company has withdrawn its fiscal 2025 guidance due to a pending acquisition deal with Sycamore Partners, expected to close in late 2025 [12][13] Financial Performance - The gross profit for Q3 was $6.51 billion, up 0.75% year-over-year, despite an 8.7% increase in the cost of sales, leading to a gross margin contraction of 108 basis points to 16.7% [8][9] - Selling, general and administrative (SG&A) expenses rose 1.6% year-over-year to $6.49 billion, with an adjusted operating profit of $13 million compared to $66 million in the previous year [10] Segment Performance - U.S. Retail Pharmacy segment sales increased by 7.8% year-over-year to $30.7 billion, with comparable sales up 10.3% [4] - International revenues grew by 7.8% year-over-year to $6.2 billion, with notable increases in Germany and Boots UK [6] - U.S. Healthcare reported revenues of $2.1 billion, with mixed performance across its sub-segments [7] Market Reaction - Following the earnings announcement, Walgreens shares rose by 0.9% in pre-market trading [2]

Core Insights - Salesforce, Inc. and Veeva Systems Inc. are prominent players in the cloud customer relationship management market, with Salesforce serving a broad range of industries and Veeva focusing exclusively on the life sciences sector [1][2] Salesforce Overview - Salesforce maintains a dominant position in the CRM market, surpassing competitors like Microsoft, Oracle, and SAP, and is transitioning to a broader enterprise software provider with a focus on AI, data, and collaboration [3][4] - The introduction of Einstein GPT in 2023 has integrated generative AI into Salesforce's platform, enhancing automation, decision-making, and customer experiences [4] - The recent launch of Agentforce, which has achieved $100 million in annualized revenues within two quarters, demonstrates Salesforce's growth momentum, with its Data Cloud also experiencing over 120% year-over-year growth in annual recurring revenues [5] - However, Salesforce is facing a slowdown in sales growth, with a revenue increase of only 7.7% and non-GAAP EPS growth of 5.7% in Q1 of fiscal 2026, attributed to cautious enterprise spending amid economic uncertainties [6][7] Veeva Systems Overview - Veeva Systems adopts a focused strategy, exclusively serving life sciences companies, which allows it to create specialized tools that are difficult to replace [8] - In Q1 of fiscal 2026, Veeva reported a non-GAAP EPS growth of 31.3% and a revenue increase of 16.7%, alongside a robust operating margin of 46.1% [9][11] - Veeva's Vault CRM, tailored for regulatory and healthcare needs, is currently utilized by over 80 clients and is expected to grow to 200 clients by next year, with ongoing expansion into data analytics and AI tools [10][12] - The company is expected to maintain strong demand for its products due to the essential nature of clinical trials and regulatory compliance in the pharmaceutical sector, even during economic downturns [12][13] Comparative Analysis - Veeva Systems is projected to have stronger growth potential, with Zacks Consensus Estimates indicating a revenue growth of 12.7% and EPS growth of 14.6% for fiscal 2026, compared to Salesforce's expected revenue growth of 8.6% and EPS growth of 10.8% [14] - In terms of valuation, Veeva trades at 35.92 times forward earnings, while Salesforce trades at 22.98 times, reflecting Veeva's higher growth momentum justifying its premium [15] - Year-to-date stock performance shows Veeva Systems has risen by 34%, while Salesforce shares have declined by 18.9%, indicating differing investor sentiment towards the two companies [16] Conclusion - Veeva Systems is positioned as the better investment choice currently, with its specialized tools, strong margins, and consistent growth in the life sciences sector, despite a higher valuation compared to Salesforce [19][20]

Core Insights - The emergence of AI is transforming enterprise software from "record systems" to "action systems," fundamentally altering the software landscape that has remained stable for decades [1][12][28] - The total IT spending on System of Record (SoR) exceeded $400 billion in 2023, including over $50 billion in maintenance costs [2] Group 1: Historical Context and Current Trends - The history of enterprise record systems parallels the evolution of enterprise computing, from mainframes in the 1960s to integrated ERP systems in the 1990s, and the rise of SaaS in the 2000s [2][3] - SoR vendors have maintained customer loyalty through high customization and deployment costs, as well as control over critical business data [6][20] - AI is beginning to dismantle these barriers, making migration and integration easier than ever before [7][8] Group 2: AI's Impact on System Migration - AI tools are automating deployment and customization, reducing implementation time by up to 90% [9] - Companies like Mechanical Orchard and Isoform are providing AI-enabled end-to-end migration services, completing complex projects in a fraction of the time [10] - New AI agents are being developed to understand specific system languages, facilitating direct script generation and breaking down data silos [11] Group 3: Redefining Data Value - AI is shifting the paradigm from "active input" to "passive extraction," allowing systems to automatically gather valuable information from various communication channels [15] - AI-native systems are not just improving efficiency but are fundamentally changing the user experience and return on investment [16][18] - The introduction of AI in CRM systems exemplifies this shift, as they now proactively guide users rather than relying on manual data entry [18] Group 4: Customer Decision-Making Dynamics - The cost of switching SoR systems has historically been high, leading to reluctance among users to change despite poor experiences [20] - AI is altering this equation by significantly reducing migration costs while offering substantial efficiency gains, prompting a potential wave of SoR replacements [21][22] - Companies that succeed in this platform-level reconstruction will likely possess characteristics such as delivering a tenfold experience difference and starting from niche markets [23][26] Group 5: Future Outlook - The transition from "record systems" to "action systems" is a gradual process, but the direction is irreversible, with SoR evolving into intelligent action engines that drive business processes [28]

Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date. However, considering it hovered near bear market territory a few weeks ago, things aren't so bad.Stocks might not be out of the woods, though. Economic issues could arise, sending markets down, as the Trump administration continues to implement its trade agenda.That said, regardless of what happens on that front, there are plenty of companies worth investing in. Here are two great examples: Netfli ...

Core Insights - Doximity, Inc. has developed a client engagement and retention strategy centered on integrated, physician-first tools across its Marketing, Hiring, and Workflow Solutions, resulting in over 620,000 unique providers using its clinical tools in Q4 of fiscal 2025 [1] Group 1: Marketing Solutions - Doximity's Marketing Solutions utilize AI and machine learning to deliver personalized campaigns, enabling pharmaceutical and health system clients to effectively reach specific clinician segments with relevant content [2] - This targeted approach has led to measurable engagement, prompting clients to broaden their usage across various brands or service lines [2] Group 2: Customer Retention Strategies - The company invests in a robust customer success team that collaborates with clients to optimize campaigns and provide ongoing analytics, which has fostered upsell opportunities and long-term relationships [3] - Clients benefit from a self-serve portal that offers real-time insights, enhancing the overall customer experience [3] Group 3: Workflow Solutions - Doximity's Workflow Solutions, such as Dialer Enterprise and AMiON, have gained significant traction and are now integrated into hospital operations, reducing the likelihood of clients transitioning away from the platform [4] - Recent innovations like Doximity GPT, an AI-powered writing assistant, further alleviate administrative burdens for clients [4] Group 4: Competitive Landscape - GoodRx Holdings, Inc. has launched Community Link to enhance pharmacy engagement through cost-plus pricing, while also introducing a new erectile dysfunction subscription service to streamline consumer access [5] - Veeva Systems Inc. is enhancing client engagement through its Vault CRM Suite, which integrates medical, sales, and service teams, and has reported momentum in products that provide real-time insights [6] Group 5: Financial Performance - Doximity's shares have increased by 9.6% year-to-date, contrasting with the industry's decline of 0.9% [7] - The Zacks Consensus Estimate indicates a 3.5% improvement in Doximity's earnings per share for fiscal 2026 compared to fiscal 2025 [9] - The company's forward 12-month P/E ratio stands at 39.4X, higher than the industry average of 14.6X but lower than its three-year median of 48.9X [12]

Core Insights - Doximity's shares have decreased by approximately 4.4% over the past month despite solid fiscal Q4 2025 results, which included revenues of $138.3 million and a 50% adjusted EBITDA margin [1][3] - For fiscal 2025, total revenues reached $570.4 million, reflecting a 20% year-over-year increase, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55% [1][4] Financial Performance - In Q4 2025, Doximity's revenues increased by 17% to $138.3 million, with an adjusted EBITDA margin of 50% [8] - The company reported a free cash flow of $97 million in Q4, contributing to a total cash position of $916 million by the end of the quarter [3][4] - Doximity raised its fiscal 2025 revenue guidance by $55-65 million to a range of $619-$631 million, indicating a 10% growth at the midpoint [5] Client Engagement and Retention - Net revenue retention reached 119% on a trailing 12-month basis, with the top 20 clients achieving a retention rate of 123% [9] - The number of customers generating over $500,000 in annual subscription revenues grew by 17% to 116, accounting for 84% of total revenues [9] Growth Drivers - Continued revenue and margin expansion were evident, with Q4 2025 top line exceeding guidance by 4% and adjusted EBITDA surpassing guidance by 10% [4] - Doximity's integrated multi-module programs and AI tools have accelerated client upsells and engagement [8] Challenges and Competition - The company faces macro and policy uncertainties, with management conservatively projecting a 5-7% growth in the pharmaceutical HCP digital market for fiscal 2026 [13] - Doximity competes with established players like Veeva Systems, Teladoc Health, and IQVIA Holdings for clinician engagement and marketing budgets [14][15] - Monetization of AI products remains low, with management acknowledging uncertainties regarding payback periods and long-term margin contributions [16] Valuation and Investment Outlook - Doximity's shares are considered overvalued, trading at a forward P/E of 36.05X compared to the sector's 14.26X [10] - The company demonstrates a profitable, high-growth business model, but challenges include macro uncertainties and competition for physician attention [20]

Core Viewpoint - Veeva Systems Inc. (NYSE: VEEV) is rated as a hold, with the stock price nearing the new intrinsic value of approximately $275 per share [1]. Group 1: Investment Strategy - The investment approach is focused on a fundamental standpoint, emphasizing a "buy & hold" strategy for the long term [1]. - The analyst highlights a long-term investment horizon, concentrating on price and margin of safety while considering risks often overlooked by short-term analysts [1]. Group 2: Performance Metrics - According to TipRanks, a success rate of 77% indicates that copying Mario Silva's trades and holding each position for one year would yield 76.92% of transactions generating a profit, with an average return of 12.20% per rating [1].

Core Insights - Astellas has selected Veeva Vault CRM globally and Veeva China CRM for its operations in China, aiming to enhance commercial agility and execution [1][2] - The collaboration with Veeva is expected to provide Astellas with technology solutions and data that align with its mission to deliver transformative therapies for patients [2] - Vault CRM is designed to meet the unique and evolving business needs and compliance requirements of the life sciences industry, facilitating seamless collaboration among sales, marketing, and medical teams [2] Company Overview - Veeva Systems is recognized as the global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [3] - The company is committed to innovation, product excellence, and balancing the interests of all stakeholders, including customers, employees, and shareholders [3]

Group 1: Marvell Technology Group Ltd. (MRVL) - Marvell Technology has seen its stock price drop 50% from January peaks ahead of its Q1 FY26 earnings release due to disappointing revenue forecasts and broader semiconductor sector weakness [2][3] - The company's valuation needed a reset after trading as high as 83X forward earnings last year, and it is currently trading at a 30% discount to its 10-year median [3][6] - Marvell's data center revenue surged 78% in Q4, driven by the AI spending boom, and it is projected to grow revenue by 44% this year and 18% next year [4][6] - Despite the recent downturn, Wall Street remains bullish on Marvell, with 25 of 31 brokerage recommendations rated as "Strong Buys" [7] Group 2: Veeva Systems (VEEV) - Veeva Systems, a cloud-based software company for the pharmaceutical and life sciences industries, has averaged 25% revenue growth over the last decade and its stock has surged 760% [9][12] - The company trades 30% below its 2021 peaks, with concerns about slowing growth and valuation impacting its stock price [12][20] - Veeva's revenue grew by 16% in fiscal 2025, driven by a 20% increase in subscription services, and it is projected to grow revenue by 11% this year and 12% next year [16][18] - The company has $5.1 billion in cash and equivalents, with minimal debt, allowing it to pursue growth opportunities and acquisitions [21]